The UAB Neurofibromatosis Clinic is looking to enroll adults with Neurofibromatosis Type 1 (NF1) for a clinical trial targeting cutaneous neurofibromas using the investigational drug called selumetinib. Cutaneous neurofibromas are the benign tumors on or in the skin that are common in adults with NF1. Study participants will take selumetinib by mouth as capsules every 12 hours for 24 cycles (one cycle equals 28 days). This study lasts approximately 2 years, unless significant side-effects develop. You may find more information regarding this clinical trial at www.clinicaltrials.gov study number NCT02839720.

**Purpose:**
The primary purpose of the trial is to determine if selumetinib can shrink cutaneous neurofibromas.

**Eligibility:**
Study participants must be at least 18 years of age with a diagnosis of NF1, have cutaneous neurofibromas that can be easily measured, and substantial neurofibroma burden causing distress, disfigurement, or itching. Participants must also be healthy enough for treatment.

**Benefits:**
Your participation would be entirely voluntary and your participation in this clinical trial may or may not make your health better. However, this study may help us better understand how to treat cutaneous neurofibromas in the future.

**Compensation and Cost of Participation:**
You will not be paid for taking part in this study. The selumetinib will be supplied at no charge while you take part in this study. You and/or your health plan (insurance company) must pay for all of the other costs of treating your tumors or other health issues while in this study, including the cost of tests, procedures, or medicines to manage any side effects, unless you are told that certain tests are supplied at no charge. Before you decide to be in the study, you should check with your health plan or insurance company to find out exactly what they will pay for. The study team will also submit an authorization letter to your insurance company requesting coverage.

**Location:**
The majority of the study visits and procedures will take place at the UAB Kirklin Clinic located at 2000 6th Ave. South, Birmingham, AL 35233.

**Selumetinib Clinical Trial Fair:** For more study details, a clinical trial fair will take place on Saturday, November 4th from 8:00 a.m. - 12:00 p.m. in the Genetic's Clinic space in the Kirklin Clinic. There will be an informational group session where the trial details will be provided. Anyone that is interested in the pursuing the trial will complete the consent forms and individually screened in a patient room. The informational session will be free of charge and the evaluation will be billed as standard of care, per protocol standards.

**Study Team:**
Principal Investigator: Bruce Korf, MD, PhD
20th Street South, Birmingham, AL 35294

For additional study questions, contact:
Ashley Cannon, PhD, MS, CGC (Study Coordinator)
Phone: 205-996-2916
Email: ashleycannon@uabmc.edu